

CASE REPORT

Open Access



# Melioidosis with a subdural collection – a case report

H. L. P. Amarasena<sup>1</sup>, F. H. D. S. Silva<sup>1</sup>, P. M. Y. I. Tilakaratna<sup>2</sup>, S. F. Jayamanne<sup>2</sup> and U. K. Ranawaka<sup>2\*</sup>

## Abstract

**Background:** Melioidosis is an infection caused by *Burkholderia pseudomallei*, which is more prevalent in the tropics and leads to significant morbidity and mortality. It characteristically produces widespread caseous lesions and abscesses, and can present with varied clinical manifestations. Melioidosis involving the central nervous system is uncommon.

**Case presentation:** A 42-year-old Sri Lankan male with type 2 diabetes presented with a febrile illness of 6 days with headache and constitutional symptoms. Clinical examination was unremarkable. Four days later, he developed focal seizures involving the left leg and numbness of the left side. Initial laboratory investigations were suggestive of a bacterial infection. Blood culture was reported as positive for a *Pseudomonas* species, which was resistant to gentamicin. Contrast enhanced CT and MRI scans of the brain showed a subdural collection in the right fronto-temporo-parietal region with possible abscess formation. Melioidosis antibody testing using indirect hemagglutination method was reactive with a titre more than 1/10,240.

He was treated with intravenous meropenem and oral co-trimoxazole for 8 weeks (Intensive phase). The subdural collection was managed conservatively, and seizures were treated with oral antiepileptics. At 7 weeks, follow-up contrast enhanced MRI showed improvement of the subdural collection, and inflammatory markers had normalized. He was discharged after 8 weeks, and treated with oral co-trimoxazole and doxycycline for 6 months (eradication phase). At 6 months follow-up, the patient is asymptomatic.

**Conclusions:** Cerebral melioidosis is an unusual presentation of melioidosis where the diagnosis can be easily missed. Knowledge of the protean manifestations of melioidosis is of paramount importance in order to detect and treat this potentially fatal infection appropriately, especially in tropical countries where the disease is endemic.

**Keywords:** Melioidosis, *Burkholderia pseudomallei*, Subdural collection, Sri Lanka

## Background

Melioidosis is an infection caused by *Burkholderia pseudomallei*, a facultative intracellular gram-negative organism, previously known as *Pseudomonas pseudomallei* [1]. It is a potentially fatal infection in humans and animals, characterized by widespread caseous lesions and abscesses. Melioidosis of the central nervous system is uncommon, and the predominant presentation is with localized collections in the brain or spinal cord. We report a case of melioidosis with a subdural collection in a Sri Lankan adult male patient.

## Case presentation

A 42-year-old Sri Lankan man presented to the Colombo North Teaching Hospital, Ragama, Sri Lanka (CNTH) with a febrile illness of 6 days, accompanied by headache and constitutional symptoms. He was a grocer from Minuwangoda, a suburban area in the Western Province situated 44 km from Colombo. He was initially investigated and treated at a regional hospital for 4 days, and was transferred to the CNTH for specialized care. He gave a history of type 2 diabetes mellitus for 5 years without microvascular or macrovascular complications, and was a nonsmoker and a teetotaler. There were no specific symptoms suggesting a source of infection such as cough, abdominal pain, urinary symptoms, etc. He was febrile with a temperature of 39.1<sup>0</sup> C, and examination of

\* Correspondence: [udayaran@yahoo.com](mailto:udayaran@yahoo.com)


<sup>2</sup>Department of Medicine, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka

Full list of author information is available at the end of the article




the heart, lungs and abdomen was unremarkable. There was no papilloedema, focal neurological signs, pyramidal signs or neck stiffness. Initial laboratory work up revealed features of a bacterial infection, with neutrophil leukocytosis and elevated inflammatory markers (erythrocyte sedimentation rate – 101 mm/1st hour, C-reactive protein - 220 mg/dl). Initial blood cultures done at the regional hospital had yielded an isolate, which was reported as a *Pseudomonas* species; this was sensitive to ceftazidime, imipenem and meropenem and resistant to gentamicin and ceftriaxone. Other basic laboratory investigations including renal and liver function tests, electrolyte panel and urinalysis were normal. Chest x-ray and ultrasound scan of the abdomen were normal, and the trans-thoracic 2-D echo did not show any vegetations. As the unusual antibiotic sensitivity pattern suggested the possibility of melioidosis, blood was sent for serological testing to a specialized Melioidosis Research Laboratory at the Faculty of Medicine, University of Colombo.

He had been initially treated with intravenous ceftriaxone, and later with ceftazidime according to the antibiotic sensitivity pattern. Although the frequency and intensity of fever spikes reduced with treatment, he continued to have low grade fever and complain of anorexia, malaise and lethargy. On the 4th day after admission to the CNTH (day 10 of the illness), he developed simple partial seizures involving the left lower limb, progressing to persistent numbness of the left side of the body. An urgent CT scan of the head revealed a subdural collection over the right fronto-parietal region with gas locules and obliteration of sulci and gyri, without definite evidence of abscess formation (Fig. 1). Contrast enhanced MRI scan of the brain demonstrated a subdural collection in the right fronto-temporo-parietal region with possible abscess formation in the right parietal region (Fig. 2). Seizures were treated with oral sodium valproate and phenytoin sodium. He was referred for neurosurgical opinion, and the subdural collection was managed conservatively. Results of the indirect hemagglutination assay (IHA) for melioidosis



**Fig. 1** Pre-treatment non-contrast computed tomography of brain showing a right fronto-parietal subdural collection with gas locules



**Fig. 2** Pre-treatment T2-weighted MRI brain (coronal view) showing a subdural collection in the right fronto-temporo-parietal region with possible abscess formation in the right parietal region

antibodies were received on the following day; an antibody titre of more than 1/10,240 was strongly suggestive of an acute infection with *Burkholderia pseudomallei* and a diagnosis of cerebral melioidosis was made.

Antibiotics were changed to intravenous meropenem and oral trimethoprim/sulfamethoxazole (Co-trimoxazole/TMP-SMX). Initial intensive therapy with these antibiotics was continued for 8 weeks, until clinical improvement was evident with resolution of inflammatory markers and radiological improvement confirmed by repeat MRI scan of the brain. (Fig. 3) Repeat blood cultures were sterile after 2 weeks of treatment with antibiotics. There were no further seizures, and the fever and the neurological symptoms resolved completely. He was discharged home with oral TMP-SMX and doxycycline, which were continued for 6 months, and the anti-epileptics were gradually tailed off. At 6 months follow up he was asymptomatic. (Fig. 4).

## Discussion and conclusions


We report a patient with melioidosis with a subdural collection, where diagnosis was a challenge mainly due

to the delayed onset and unusual nature of the neurological presentation.

The diagnosis was initially suspected based on a blood culture which was reported as ‘positive for *Pseudomonas* spp.’ but with an antibiotic sensitivity pattern which suggested melioidosis. This report highlights the need to actively search for foci of infection when no obvious focus is evident.

Melioidosis is predominantly a disease endemic to tropical regions. It was first reported in 1912 by Whitmore and Krishnaswami, who described 38 cases of a “hitherto undescribed glanders-like illness” in the Rangoon General Hospital, Burma [2]. The highest reported prevalence rates are seen in South Asia, Southeast Asia and Northern Australia [3–6]. South Asia bears 44% of the disease burden, while 40% is shared by the East Asia and Pacific regions [5].

*B. pseudomallei* infection is acquired primarily through percutaneous inoculation [7]. Inhalation is another common mode of acquiring the disease. During severe weather conditions such as monsoon storms, hurricanes, typhoons and cyclones, the organism is released into the air and the predominant mode of transmission




**Fig. 3** Post-treatment T2-Weighted MRI brain (coronal view) showing resolution of the subdural collection

shifts from inoculation to inhalation [4]. This was seen following the Indian Ocean tsunami of December 2004, when melioidosis was implicated in the so-called ‘Tsunami Lung’ phenomenon; people swept by tsunami waves developed pneumonia following aspiration of salt water mixed with mud contaminated with bacteria [8–10].

Melioidosis involving the central nervous system (CNS) is rare (seen in about 5%) [11], and can present in many ways including brain and epidural abscesses, encephalomyelitis (predominantly involving the brainstem), aseptic meningitis, dural venous sinus thrombosis and transverse myelitis [4, 12–17]. Isolated subdural collections associated with melioidosis, as seen in our patient, are rarely reported [12–14, 18–20]. A study from Darwin, Australia reported 14 cases with neurological involvement among 540 patients with melioidosis (10 with meningo-encephalitis, 2 with myelitis and 2 with cerebral abscesses); there were no cases of subdural

collections [11]. A series of 169 patients with melioidosis in East Malaysia had 3 patients with neurological involvement, and only one of them had a subdural collection which was associated with a brain abscess [12].

The first report of melioidosis from Sri Lanka was in a European tea broker in 1927 [21], and only a few additional cases were reported until recently. However, a laboratory-based case finding program (Sri Lanka National Melioidosis Surveillance Programme) found 32 cases of culture confirmed melioidosis between 2006 and 2014. Cases were reported in 8 of the 9 provinces of the island, with the exception of the Sabaragamuwa Province which consists predominantly of tea and rubber growing highland areas. An increase in incidence was seen with rainfall, especially in the rice growing lowlands, and the annual peak in melioidosis was seen around October when rainfall is highest in the Western Province [22]. The recent increase in reported numbers



may well be due to better awareness and detection, but it will be interesting to explore whether the 2004 tsunami that had such a devastating impact on Sri Lanka had any influence on the increase in reported incidence. It is pertinent to note that serological evidence of increased exposure to *B. pseudomallei* was reported from Southern Thailand following the 2004 tsunami, both in tsunami survivors and those unaffected [23].

The first reported case of CNS melioidosis related to Sri Lanka was in a European traveler who developed brain and lung abscesses following a 15-day visit [17]. Cases of cerebral abscess [22], transverse myelitis [16],

and Guillain-Barre syndrome [24] have been reported more recently.

Culture is the gold standard in the diagnosis of melioidosis. *B. pseudomallei* grows easily in usual culture media, but can be easily mistaken for *Pseudomonas spp.*, especially in non-endemic areas where clinical suspicion of melioidosis would be low and facilities and expertise needed for diagnosis are lacking [4]. The organism is easily outgrown in culture media by faster growing species such as commensals in specimens from non-sterile sites, which can lead to a missed or incorrect diagnosis [25]. The antibiotic sensitivity pattern can provide an

important clue to the diagnosis; *B. pseudomallei* is characteristically resistant to the commonly used antimicrobials such as penicillin, ampicillin, first or second-generation cephalosporins, gentamicin, tobramycin and streptomycin [3]. Culturing the organism in Ashdown's agar containing gentamicin or Ashdown's broth containing colistin facilitates identification of *B. pseudomallei* [4].

Serology can be helpful in the diagnosis of melioidosis, especially in the presence of high antibody titres. Indirect hemagglutination assay (IHA) is the most widely used serological test, with the sensitivity ranging from 56 to 80% [26, 27] and specificity ranging from 75 to 91% [27, 28]. According to recent data, the background sero-positivity for melioidosis in Sri Lanka is estimated to be 7.4% at a titre of 1/40 [29]. This contrasts with the background sero-positivity in populations with a higher exposure to melioidosis such as Thailand which can be as high as 80% [30] and could have a negative impact on the sensitivity of serological tests.

All patients with melioidosis require an initial intensive therapy with intravenous meropenem, imipenem or ceftazidime for at least 2 weeks. Continuation of intensive therapy for a period of 4 to 8 weeks or longer is recommended for patients who are critically ill or have extensive pulmonary disease, deep seated collections or organ abscesses, osteomyelitis, septic arthritis or neurological melioidosis. Addition of trimethoprim/sulfamethoxazole (TMP-SMX) should be considered for deep seated infections. Drainage of abscesses should also be considered where applicable [4]. It is recommended that the intensive phase is followed by a prolonged period of oral antibiotic therapy of at least 12 weeks to eradicate the organism, but the optimum antibiotic regimen and duration of the eradication phase remain uncertain [31]. Combination therapy with oral TMP-SMX and doxycycline was traditionally recommended [32], but a recent multicenter trial has shown that monotherapy with TMP-SMX for a period of 20 weeks was non-inferior and associated with less adverse events [33].

Melioidosis is not included in the list of notifiable diseases in Sri Lanka, and this should be strongly considered as the incidence of melioidosis appears to be increasing. Melioidosis is a treatable disease, but treatment is difficult and relapses are common [7]. Early recognition is imperative for optimal treatment, but diagnosis can be challenging, as seen in our patient. Facilities for diagnosis should be readily available, especially in the endemic regions. Sri Lanka, and other countries in endemic regions, would do well to invest in providing advanced training for clinicians and microbiologists and developing teams of local experts to ensure delivery of appropriate care. National treatment guidelines should be developed, taking into consideration the availability of facilities and regional variations in disease

prevalence. Clearly, more research is needed to understand the differences in epidemiology and transmission patterns across countries. A high degree of suspicion is required to diagnose this evasive illness, and improving awareness on melioidosis among the public and the medical community is of paramount importance.

#### Abbreviations

CNS: Central nervous system; CNTH: Colombo North Teaching Hospital; CT: Computed tomography; MRI: Magnetic resonance imaging; TMP-SMX: Trimethoprim/sulfamethoxazole

#### Acknowledgements

The authors would like to acknowledge the contribution of Dr. Enoka Corea, Consultant Microbiologist of the Faculty of Medicine, Colombo in managing this patient.

#### Funding

No funding source.

#### Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

#### Authors' contributions

HPLA wrote the initial draft. HPLA and UKR did the subsequent revisions and wrote the final version. HPLA, FHDSS, PMYIT, SFJ and UKR were actively involved in the management of the patient. All authors contributed to the revisions and read and approved the final manuscript.

#### Ethics approval and consent to participate

Not applicable to this article as this is a case report.

#### Consent for publication

Written and informed consent was obtained from the patient to publish this case report and to use the accompanying images.

#### Competing interests

The authors declare that they have no competing interests.

#### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Author details

<sup>1</sup>Professorial Medical Unit, Colombo North Teaching Hospital, Ragama, Sri Lanka. <sup>2</sup>Department of Medicine, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka.

Received: 12 January 2018 Accepted: 6 February 2019

Published online: 12 February 2019

#### References

- White NJ. Melioidosis. *Lancet*. 2003;361:1715–22.
- Whitmore A, Krishnaswami CS. An account of the discovery of a hitherto undescribed infective disease occurring among the population of Rangoon. *Ind Med Gaz*. 1912;47:262–7.
- Dance DA. Melioidosis: the tip of the iceberg? *Clin Microbiol Rev*. 1991;4:52–60.
- Currie BJ. Melioidosis: evolving concepts in epidemiology, pathogenesis and treatment. *Semin Respir Crit Care Med*. 2015;36:111–25.
- Limmathurotsakul D, Golding N, Dance DA, Messina JP, Pigott DM, Moyes CL, et al. Predicted global distribution of *Burkholderia pseudomallei* and burden of melioidosis. *Nat Microbiol*. 2016;1:1.
- Currie BJ, Fisher DA, Howard DM, Burrow JNC, Selvanayagam S, Snelling PL, et al. The epidemiology of melioidosis in Australia and Papua New Guinea. *Acta Trop*. 2000;74(2–3):121–7.
- Limmathurotsakul D, Peacock SJ. Melioidosis: a clinical overview. *Br Med Bull*. 2011;99:125–39.

8. Potera C. In disaster's wake: Tsunami lung. *Environ Health Perspect.* 2005; 113:734–7.
9. Chierakul W, Winothai W, Wattanawaitunechai C, Wuthiekanun V, Rugtaengan T, Rattanaalernavee J, et al. Melioidosis in 6 tsunami survivors in southern Thailand. *Clin Infect Dis.* 2005;41:982–90.
10. Athan E, Allworth AM, Engler C, Bastian I, Cheng AC. Melioidosis in Tsunami Survivors. *Emerg Infect Dis.* 2005;11:1638–9.
11. Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. *PLoS Negl Trop Dis.* 2010;4:e900.
12. Fong SL, Wong JS, Tan AH, Low SC, Tan CT. Neurological melioidosis in East Malaysia: case series and review of the literature. *Neurol Asia.* 2017;22:25–32.
13. Kuan YC, How SH, Ng TH, Fauzi AR. The man with the boggy head: cranial melioidosis. *Singap Med J.* 2010;51(2):43–5.
14. Saravu K, Kadavigere R, Shastry BA, Pai R, Mukhopadhyay C. Neurologic melioidosis presented as encephalomyelitis and subdural collection in two male labourers in India. *J Infect Dev Ctries.* 2015;9:1289–93.
15. Pit S, Chea FK, Jamal F. Melioidosis with brain abscess. *Postgrad Med J.* 1988;64(748):140–2.
16. Nandasiri S, Wimalaratna H, Manjula M, Corea E. Transverse myelitis secondary to melioidosis: a case report. *BMC Infect Dis.* 2012;12:232.
17. Peetermans WE, Van Wijngaerden E, Van Eldere J, Verhaegen J. Melioidosis brain and lung abscess after travel to Sri Lanka. *Clin Infect Dis.* 1999;28:921–2.
18. Muthusamy KA, Waran V, Puthuchery SD. Spectra of central nervous system melioidosis. *J Clin Neurosci.* 2007;14:1213–5.
19. Madi D, Rai SPV, Vidyakshmi K, Chowta KN. Neurological melioidosis presenting as intracranial abscess. *Indian J Pathol Microbiol.* 2016;59:417–9.
20. Saravu K, Vishwanath S, Kumar RS, Barkur AS, Varghese GK, Mukhyopadhyay C, et al. Melioidosis – a case series from South India. *Trans R Soc Trop Med Hyg.* 2008;102:S18–20.
21. Denny CR. Melioidosis in a European. *Ceylon J Sci.* 1927;2:37–40.
22. Corea EM, Merritt AJ, Ler YH, Thevanesam V, Inglis TJJ. Sri Lankan national melioidosis surveillance program uncovers a nationwide distribution of invasive melioidosis. *Am J Trop Med Hyg.* 2016;94:292–8.
23. Wuthiekanun V, Chierakul W, Rattanaalernavee J, Langa S, Sirodom D, Wattanawaitunechai C, et al. Serological evidence for increased human exposure to *Burkholderia pseudomallei* following the tsunami in southern Thailand. *J Clin Microbiol.* 2006;44:239–40.
24. Wijekoon PW, Bandara KA, Kailainathan A, Chandrasiri NS, Hapuarachchi CT. Guillaine-Barre syndrome; a rare complication of melioidosis. A case report. *BMC Infect Dis.* 2016;16:388.
25. Inglis TJJ, Rolim DB, De Queiroz Sousa A. Melioidosis in the Americas. *Am J Trop Med Hyg.* 2006;75:947–54.
26. Cheng AC, O'Brien M, Freeman K, Lum G, Currie BJ. Indirect hemagglutination assay in patients with melioidosis in northern Australia. *Am J Trop Med Hyg.* 2006;74:330–4.
27. O'Brien M, Freeman K, Lum G, Cheng AC, Jacups SP, Currie BJ. Further evaluation of a rapid diagnostic test for melioidosis in an area of endemicity. *J Clin Microbiol.* 2004;42:2239–40.
28. Dharakul T, Songsivilai S, Anuntagool N, Chaowagul W, Wongbunnate S, Intachote P, Sirisinha S. Diagnostic value of an antibody enzyme-linked immunosorbent assay using affinity-purified antigen in an area endemic for melioidosis. *Am J Trop Med Hyg.* 1997;56:418–23.
29. Corea E, de Silva A, Thevanesam V. Melioidosis in Sri Lanka. *Trop Med Infect Dis.* 2018;3:22.
30. Kanaphun P, Thirawattanasuk N, Suputtamongkol Y, Naigowit P, Dance DA, Smith MD, White NJ. Serology and carriage of *Pseudomonas pseudomallei*: a prospective study in 1000 hospitalized children in Northeast Thailand. *J Infect Dis.* 1993;167:230–3.
31. Fisher DA, Harris PNA. Melioidosis: refining management of a tropical time bomb. *Lancet.* 2014;383:762–4.
32. Inglis TJJ. The treatment of Melioidosis. *Pharmaceuticals.* 2010;3:1296–303.
33. Chetchotisakd P, Chierakul W, Chaowagul W, Anunnatsiri S, Phimda K, Mootsikapun P, Chaisuksant S, Pilaikul J, Thinkhamrop B, Phiphitaporn S, et al. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradication treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. *Lancet.* 2014;383:807–14.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

